Long-term follow-up and late effects of childhood cancer: Viva

Branching clinical structured oral on the long-term follow-up and late effects of childhood cancer, covering the treatment-summary-driven and risk-stratified surveillance, the dose-dependent anthracycline cardiomyopathy, the radiation-associated breast cancer, the endocrine and neurocognitive late effects, the fertility implications of the gonadotoxic therapy, the acute presentations of the late effects, and the structured transition of the adolescent to the adult late-effects service.

branching clinical structured oral5 min readVerification in progress

Prompt

A twenty-two-year-old woman attends the survivorship clinic fifteen years after the treatment of a childhood Hodgkin lymphoma with a cumulative anthracycline dose of three hundred milligrams per square metre and chest radiation of thirty gray. She reports increasing exercise intolerance. The examiner asks how you frame the problem, how you build the risk-stratified surveillance, how you manage the cardiac and the oncologic late effects, and how you counsel her on the fertility and the transition.

This is a branching oral built to probe the reasoning that holds the treatment exposure and the risk-based surveillance at the centre, and to expose the candidate who has memorised the headline without the corners. The questions escalate from the framing to the surveillance, the cardiac and the oncologic management, and the transition, with the deliberate probes into the pitfalls. ^[2]

Opening question: framing the problem

The examiner opens with the history and asks: how do you frame this problem in a single sentence, and what is your first priority? ^[1]

A strong answer names the childhood cancer survivor with the high-risk treatment exposures for the anthracycline cardiomyopathy and the radiation-associated breast cancer, and states that the exercise intolerance demands the urgent cardiac assessment. The first priority is the echocardiogram, because the cumulative anthracycline dose of three hundred milligrams per square metre exceeds the high-risk threshold of two hundred and fifty milligrams per square metre, and the cardiomyopathy can be silent for years before the heart failure declares. ^[5]

Model answer. This woman is a childhood cancer survivor at high risk of the anthracycline cardiomyopathy, because her cumulative anthracycline dose of three hundred milligrams per square metre exceeds the two hundred and fifty milligrams per square metre threshold, and her exercise intolerance demands the urgent echocardiogram and the cardio-oncology referral. My first priority is the cardiac assessment, and my second is the comprehensive risk-stratified surveillance built on her treatment summary. ^[5]

References6Show

[1]Oeffinger KC, Mertens AC, Sklar CA Chronic health conditions in adult survivors of childhood cancer N Engl J Med, 2006.PMID 17035650
[2]DeVine A, Landier W, Hudson MM The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review JAMA Oncol, 2025.PMID 39976936
[5]Leerink JM, de Baat EC, Feijen EAM Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review JACC CardioOncol, 2020.PMID 34396245
[3]Chemaitilly W, Cohen LE, Mostoufi-Moab S Endocrine Late Effects in Childhood Cancer Survivors J Clin Oncol, 2018.PMID 29874130
[9]Armstrong GT, Liu W, Leisenring W Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study J Clin Oncol, 2011.PMID 21709189
[11]Fardell JE, Wakefield CE, Signorelli C Transition of childhood cancer survivors to adult care: The survivor perspective Pediatr Blood Cancer, 2017.PMID 28436208